Paolo A. Ascierto, Full Professor of Oncology at the University of Naples Federico II and Director of the Department of Melanoma, Cancer Immunotherapy and Developmental Therapeutics at the Istituto Nazionale Tumori IRCCS Fondazione Pascale in Naples, Italy, shared on LinkedIn:
“mRNA-Based Vaccines: A New Chapter in Melanoma Treatment and Precision Oncology
Today, at ESMO in Madrid, we presented the results of the Phase III INTerpath-001 trial, marking an important step forward in the development of personalized approaches to melanoma treatment.
By combining an mRNA-based vaccine with immunotherapy, we are moving beyond a one-size-fits-all approach towards a treatment strategy tailored to the unique genetic profile of each patient’s tumor.
The 2-year results are encouraging:
- 82.2% of patients were alive and recurrence-free, compared with 70.0% of patients receiving immunotherapy alone.
- 88.5% of patients remained free of distant metastases.
- A 42% reduction in the risk of recurrence or death, increasing to 58% after the first six months.
This personalized therapeutic approach is designed to train the immune system, particularly T cells, to recognize and eliminate residual tumor cells. Preventing recurrence remains a key objective in improving long-term outcomes for patients with melanoma.
These findings highlight the potential of personalized mRNA-based strategies to further advance precision oncology and reinforce the importance of continued clinical research.
My sincere thanks to all the patients and their families, the investigators, researchers, and clinical teams whose commitment makes this progress possible.”
You can also read: INTerpath-001 Trial: Personalized mRNA Cancer Vaccine in High-Risk Melanoma
